AGTC Genomics Partners with IMU Healthcare, MOSTA and KLK OLEO to Advance Cutting-Edge Healthy Ageing Clinical Research

AGTC Genomics is proud to be among the organisations supporting a pioneering clinical research study investigating whether a natural palm-based tocotrienol-rich fraction, a form of vitamin E, may influence healthy ageing through measurable markers of cellular ageing.

The study brings together expertise and support from IMU Healthcare, the Malaysian Oil Scientists’ and Technologists’ Association (MOSTA), KLK OLEO and AGTC Genomics, combining clinical research, palm-based innovation and advanced biomedical science. The study will be conducted at IMU Healthcare Clinic, Bukit Jalil, Kuala Lumpur. The research has also been reviewed and approved by the IMU Joint Committee on Research and Ethics (IMU R 346-2026), underscoring the study's commitment to appropriate ethical and scientific oversight.

Advancing the Science of Healthy Ageing

As populations around the world live longer, the focus of healthcare is increasingly shifting from simply extending lifespan to extending healthspan — the years of life spent in good health and with greater functional independence.

This study is particularly significant because it examines ageing at the cellular level, an emerging frontier in preventive and precision health. Rather than relying solely on age or conventional health measurements, the research will investigate whether nutritional intervention with a naturally derived tocotrienol-rich fraction may influence biological markers associated with the ageing process.

The nine-month study will involve Malaysian adults aged 50 to 70 years who are generally in good health and able to complete four study visits. Participants will receive complimentary health assessments, blood tests and medical reviews throughout the study.

Bringing Precision Science into Healthy Ageing Research

For AGTC Genomics, supporting the study reflects the company's commitment to advancing the next generation of preventive and precision healthcare.

"The future of healthy ageing will increasingly be driven by our ability to measure biological changes before they become visible as disease," said Professor Chee-Onn Leong, Founder and CEO of AGTC Genomics. "What makes this study exciting is its focus on cellular ageing. By objectively studying how an intervention may influence biological markers over time, we can begin moving healthy ageing research towards a more measurable, evidence-driven and personalised approach."

The study is at the cutting edge of an important transition in modern medicine: from treating disease after it develops towards understanding the biological processes that may influence long-term health much earlier.

Longitudinal research of this nature is also important because ageing is a complex and dynamic biological process. Following participants over a nine-month period provides researchers with an opportunity to examine changes over time rather than relying on a single snapshot of health.

Unlocking the Potential of Malaysia's Palm-Based Bioactives

The research also carries particular relevance for Malaysia. Tocotrienols are naturally occurring members of the vitamin E family and can be derived from palm sources. Scientifically evaluating their potential role in healthy ageing could contribute to the growing body of evidence surrounding locally relevant natural bioactives while supporting the development of higher-value research and innovation originating from Malaysia.

Professor Leong added:

"Malaysia has the opportunity to combine its strengths in natural bioresources with advanced biomedical science. The real breakthrough comes when promising compounds are evaluated through carefully designed human studies using objective biological measurements. This is how we turn scientific potential into evidence that can ultimately contribute to better healthcare."

Contributing to the Future of Preventive Healthcare

Beyond investigating a specific nutritional intervention, the study may contribute to a broader understanding of how healthy ageing can be studied and monitored using measurable biological indicators.

This approach is closely aligned with the future direction of precision health, where interventions may increasingly be evaluated according to an individual's biological response rather than through a one-size-fits-all model.

Participants will also have the opportunity to contribute directly to research that may advance knowledge in healthy ageing and support the development of improved healthcare approaches.

Study Recruitment

The study is currently inviting eligible Malaysian adults aged 50 to 70 years to register their interest. Participants must be generally in good health, including those with stable and well-controlled medical conditions, and be willing to complete the nine-month study involving four visits.

Registration of interest is open until 30 October 2026, with the study taking place at IMU Healthcare Clinic, Bukit Jalil, Kuala Lumpur.

---

About AGTC Genomics

AGTC Genomics is a Malaysia-based precision medicine and genomics company focused on translating advanced genomic and molecular technologies into clinically meaningful solutions. Through its work in precision oncology, preventive health, genomic medicine and advanced molecular diagnostics, AGTC Genomics is committed to supporting a future in which healthcare becomes increasingly predictive, preventive and personalised.